 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease |
| Udayakumar Karunakaran, Nam Ho Jeoung |
|
Diabetes Metab J. 2010;34(4):211-219. Published online August 31, 2010 DOI: https://doi.org/10.4093/kdj.2010.34.4.211 |
|
O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease Korean Diabetes Journal. 2010;34(4):211  Insulin treatment and cardiovascular disease; friend or foe? A point of view Diabetic Medicine. 2005;22(2):118-126 NF-κB in transplantation: friend or foe? Transplant Infectious Disease. 2001;3(4):212-219 Resource Management: Friend or Foe? Diabetic Medicine. 1992;9(6):501-502 Coffee: friend or foe for diabetes risk? Diabetic Medicine. 2014;31(7):763-763 Prokineticin Receptors in Cardiovascular Function: Foe or Friend? Trends in Cardiovascular Medicine. 2009;19(2):55-60 S-glutathionylation, friend or foe in cardiovascular health and disease Redox Biology. 2020;37:101693 False Tendon in Cardiovascular Diseases: Friend, Foe, or Bystander? Journal of Cardiovascular Imaging. 2021;29(1):57 Tofacitinib in cardiovascular outcomes: friend or foe? Rheumatology. 2020;59(8):1797-1798 Editorial commentary: Technology to treat heart failure: Friend or foe? Trends in Cardiovascular Medicine. 2018;28(7):489-490 |
